Does this job make me look fat? A Gallup-Healthways survey takes a look at which jobs have high rates of obesity. And it's bad news for bus drivers.» Read More
WASHINGTON, May 8- A U.S. House of Representatives panel advanced a bill on Wednesday on how the federal government should track prescription drugs as they move through the distribution chain, over the objections of some Democrats who said the proposal did not go far enough to ensure safety.
After approvals last year from the FDA for 39 novel medicines- a record only beaten in 1996- the healthy pace has continued into 2013.. And drugmakers are getting further help from a new FDA program to accelerate life-saving therapies designated as a "breakthrough," opening to door to earlier approval based on quicker studies, where clinical data is compelling.
NEW YORK-- Shares of Alexza Pharmaceuticals Inc. jumped Wednesday after the company said Teva Pharmaceutical Industries Ltd., one of the world's largest drug companies, will market is agitation drug Adasuve in the U.S.
Recently published health care figures from the federal government confirm what health advocates have been screaming about for years: charges vary enormously, NBC News reports.
For the first time ever, the government is going to release data on what medical care actually costs, reports CNBC's Hampton Pearson.
Shares of Jazz Pharmaceuticals PLC slid Wednesday morning, a day after the Irish drugmaker said in a regulatory filing that the Food and Drug Administration could approve a competitor's generic version of its top-seller, narcolepsy treatment Xyrem.
Health care and technology, not banking and finance, top millennials' choice for careers, according to a new survey. See which companies they would prefer to work. St. Jude hospital?
Berkshire Hathaway and dialysis maker DaVita Healthcare entered into an agreement under which Berkshire will not increase its stake above 25 percent.
NEW YORK-- Shares of Santarus Inc. jumped Tuesday after the biopharmaceutical company posted strong first-quarter results and raised its forecast for the full year. THE SPARK: Santarus reported its quarterly results after the market closed on Monday.
*Bankers expect steady flow of $1 bln to $5 bln pharma deals. The stock valuations of companies like Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Celgene Corp and Biogen Idec Inc have skyrocketed in the past year or two alone, making it difficult for large pharmaceutical companies to buy them and leaving a trail of dead deals.
LEXINGTON, Mass.-- Cubist Pharmaceuticals Inc. said Tuesday that the Food and Drug Administration has given fast-track status to an experimental antibiotic regimen as a treatment for three types of infections. In February, the FDA granted fast-track status for the drug regimen as a treatment for complicated intra-abdominal infections.
One of the economic mysteries of the last few years has been the bigger-than-expected slowdown in health spending.
May 7- Cubist Pharmaceuticals Inc:. *FDA grants fast track designation for cubist's late-stage antibiotic. *Says expects to initiate a phase 3 vabp program for ceftolozane/tazobactam by.
Gregory Sorenson, President and CEO of Siemens Healthcare North America, discusses repealing the medical device tax.
More than 70 percent of those responding to a recent survey by Merrill Lynch said that outliving their good health was more of a concern than outliving their money.
The Internal Revenue Service will play an important role in how health-care reform is managed, even deciding who will have to buy coverage.
In a first for the drug industry, Pfizer told The Associated Press that the drugmaker will begin selling its popular erectile dysfunction pill Viagra directly to patients on its website.
*FDA clears Masimo rainbow acoustic Monitoring (TM) sensor for use on.
Following is Cramer's homework on a lesser-known stock called to his attention by viewers.
May 3- The U.S. Food and Drug Administration approved a Merck& Co. cholesterol lowering pill that combines a generic version of Pfizer Inc's Lipitor with its own Zetia, Merck said on Friday. Vytorin, which had sales of $1.75 billion in 2012, is currently undergoing a long-term trial to prove that it can reduce heart attacks and strokes better than Zocor alone.